31 October
2024
IXICO PLC
("IXICO" or
the "Company")
Share Option
Awards
PDMR
Dealing
IXICO plc (AIM: IXI), the medical
imaging advanced analytics company delivering insights in
neurosciences, today announces that, further to the announcements
made on 8 October 2024 in respect of the Company's proposal to
issue share options, and on 25 October 2024 in respect of the
approval at the General Meeting of the Company's new EMI Share
Option Plan, the Company has issued a total of 3,520,058 share
options (the "Share Options") as follows:
Growth options:
Share Options over 2,780,058 shares
have been awarded to the Bram Goorden, CEO and Grant Nash, CFO of
the Company. These Growth Share Options have vesting criteria
aligned with retention and annual share price growth over 3
years. Of these, 1,853,372 options (equivalent to 2% of
issued share capital) have been issued to the CEO, Bram Goorden,
and 926,686 options (equivalent to 1% of issued share capital) have
been issued to the CFO, Grant Nash. These options have an
exercise price of £0.01 and will be subject to a hold period to the
third anniversary of their award.
The achievement of share price
growth each year shall be measured by calculating the 3-month
average share price immediately prior to each anniversary of the
option award. The growth performance can be met in full by an
absolute compound share price growth of 40% over the three-year
period or in part by a 40% share price growth as compared to the
prior year. In the first year this shall be compared to a baseline
price equivalent to the three-month average share price immediately
prior to the CEO joining the Company on 19 August 2024.
Retention options:
Share Options over a further 740,000
shares are awarded to the broader leadership team of the Company,
including 200,000 Share Options awarded to the Robin Wolz, CSO who
is treated as a PDMR. These Share Options have an exercise
price of £0.0925 and have vesting criteria aligned with retention
of these individuals in the business across 3 years.
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited
(Nominated adviser and sole broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan
Hodkinson (Corporate
Finance)
|
|
|
Nigel Birks (Life Sciences
Specialist Sales)
|
|
|
Harriet Ward (Corporate
Broking)
|
|
|
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is available
on www.IXICO.com and follow us on X
(formerly Twitter) @IXICOnews
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Bram Goorden
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
IXICO plc
|
|
b)
|
LEI
|
2138005M1F59O6HWSA97
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over ordinary shares in
IXICO plc
|
|
|
|
|
Identification code
|
ISIN: GB00BFXR4C20
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of Share Options
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
1 pence
|
1,853,372
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
N/A - single transaction
|
|
- Aggregated volume
|
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
30 October 2024
|
|
f)
|
Place of the transaction
|
Off Market Transaction
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Grant Nash
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
IXICO plc
|
|
b)
|
LEI
|
2138005M1F59O6HWSA97
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over ordinary shares in
IXICO plc
|
|
|
|
|
Identification code
|
ISIN: GB00BFXR4C20
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of Share Options
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
1 pence
|
926,686
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
N/A - single transaction
|
|
- Aggregated volume
|
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
30 October 2024
|
|
f)
|
Place of the transaction
|
Off Market Transaction
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Robin Wolz
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Scientific Officer and
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
IXICO plc
|
|
b)
|
LEI
|
2138005M1F59O6HWSA97
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over ordinary shares in
IXICO plc
|
|
|
|
|
Identification code
|
ISIN: GB00BFXR4C20
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of Share Options
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
9.25p
|
200,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
N/A - single transaction
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
30 October 2024
|
|
f)
|
Place of the transaction
|
Off market
|
